MicroRNA Expression in Acute Myeloid Leukemia

Overview

Journal Curr Hematol Malig Rep

Publisher Current Science

Specialties Hematology
Oncology

Date 2010 Apr 29

PMID 20425419

Citations 23

Authors

Guido Marcucci

Michael D Radmacher

Krzysztof Mrozek

Clara D Bloomfield

Affiliations

Soon will be listed here.

Abstract

Acute myeloid leukemia (AML) is a group of diseases that are very heterogeneous with regard to cytogenetic aberrations, gene mutations, and changes in expression of numerous genes. A new class of genes known as microRNAs recently was found to be involved in myeloid leukemogenesis. These genes are transcribed into regulatory, noncoding RNAs that control mRNA and protein expression of target genes. Genome-wide analyses of microRNA expression have revealed signatures associated with selected cytogenetic and molecular subsets of AML and have led to the recognition of previously unreported molecular pathways involved in myeloid leukemogenesis. In cytogenetically normal AML, microRNA-expression profiling has also provided prognostic information in addition to that obtained from cytogenetics and analyses of gene mutations and aberrant gene expression. This article reviews recent studies that were focused on the alterations of microRNA expression in AML and their diagnostic and prognostic significance.

Citing Articles

Over-expression of mir-181a-3p in serum of breast cancer patients as diagnostic biomarker.

Fouladi H, Ebrahimi A, Mansoori Derakhshan S, Shekari Khaniani M Mol Biol Rep. 2024; 51(1):372.

PMID: 38411870 DOI: 10.1007/s11033-024-09272-4.

Targeting miR-126 in inv(16) acute myeloid leukemia inhibits leukemia development and leukemia stem cell maintenance.

Zhang L, Truong Nguyen L, Chen Y, Wu D, Cook G, Hoang D Nat Commun. 2021; 12(1):6154.

PMID: 34686664 PMC: 8536759. DOI: 10.1038/s41467-021-26420-7.

MicroRNA-181a-3p as a Diagnostic and Prognostic Biomarker for Acute Myeloid Leukemia.

Qiang P, Pan Q, Fang C, Fozza C, Song K, Dai Y Mediterr J Hematol Infect Dis. 2020; 12(1):e2020012.

PMID: 32180907 PMC: 7059742. DOI: 10.4084/MJHID.2020.012.

Aberrant Expression of the miR-181b/miR-222 after Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia.

Iravani Saadi M, Arandi N, Yaghobi R, Azarpira N, Geramizadeh B, Ramzi M Indian J Hematol Blood Transfus. 2019; 35(3):446-450.

PMID: 31388255 PMC: 6646491. DOI: 10.1007/s12288-018-01066-6.

MiR-9 functions as a tumor suppressor in acute myeloid leukemia by targeting CX chemokine receptor 4.

Zhu B, Xi X, Liu Q, Cheng Y, Yang H Am J Transl Res. 2019; 11(6):3384-3397.

PMID: 31312352 PMC: 6614627.

References

Heuser M, Beutel G, Krauter J, Dohner K, von Neuhoff N, Schlegelberger B . High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. Blood. 2006; 108(12):3898-905. DOI: 10.1182/blood-2006-04-014845. View

Langer C, Radmacher M, Ruppert A, Whitman S, Paschka P, Mrozek K . High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B.... Blood. 2008; 111(11):5371-9. PMC: 2396728. DOI: 10.1182/blood-2007-11-124958. View

Garzon R, Volinia S, Liu C, Fernandez-Cymering C, Palumbo T, Pichiorri F . MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood. 2008; 111(6):3183-9. PMC: 2265455. DOI: 10.1182/blood-2007-07-098749. View

Dixon-McIver A, East P, Mein C, Cazier J, Molloy G, Chaplin T . Distinctive patterns of microRNA expression associated with karyotype in acute myeloid leukaemia. PLoS One. 2008; 3(5):e2141. PMC: 2373886. DOI: 10.1371/journal.pone.0002141. View

Mariathasan S, Monack D . Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation. Nat Rev Immunol. 2006; 7(1):31-40. DOI: 10.1038/nri1997. View

Jongen-Lavrencic M, Sun S, Dijkstra M, Valk P, Lowenberg B . MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood. 2008; 111(10):5078-85. DOI: 10.1182/blood-2008-01-133355. View

Isken F, Steffen B, Merk S, Dugas M, Markus B, Tidow N . Identification of acute myeloid leukaemia associated microRNA expression patterns. Br J Haematol. 2008; 140(2):153-61. DOI: 10.1111/j.1365-2141.2007.06915.x. View

Dohner K, Dohner H . Molecular characterization of acute myeloid leukemia. Haematologica. 2008; 93(7):976-82. DOI: 10.3324/haematol.13345. View

Byrd J, Mrozek K, Dodge R, Carroll A, Edwards C, Arthur D . Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002; 100(13):4325-36. DOI: 10.1182/blood-2002-03-0772. View

10.

Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G . The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998; 92(7):2322-33. View

11.

Mrozek K, Marcucci G, Paschka P, Whitman S, Bloomfield C . Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?. Blood. 2006; 109(2):431-48. PMC: 1785102. DOI: 10.1182/blood-2006-06-001149. View

12.

Hackanson B, Bennett K, Brena R, Jiang J, Claus R, Chen S . Epigenetic modification of CCAAT/enhancer binding protein alpha expression in acute myeloid leukemia. Cancer Res. 2008; 68(9):3142-51. DOI: 10.1158/0008-5472.CAN-08-0483. View

13.

Calin G, Sevignani C, Dumitru C, Hyslop T, Noch E, Yendamuri S . Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A. 2004; 101(9):2999-3004. PMC: 365734. DOI: 10.1073/pnas.0307323101. View

14.

Radmacher M, Marcucci G, Ruppert A, Mrozek K, Whitman S, Vardiman J . Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study. Blood. 2006; 108(5):1677-83. PMC: 1895508. DOI: 10.1182/blood-2006-02-005538. View

15.

Metzeler K, Hummel M, Bloomfield C, Spiekermann K, Braess J, Sauerland M . An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood. 2008; 112(10):4193-201. PMC: 2954679. DOI: 10.1182/blood-2008-02-134411. View

16.

Marcucci G, Maharry K, Whitman S, Vukosavljevic T, Paschka P, Langer C . High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol. 2007; 25(22):3337-43. DOI: 10.1200/JCO.2007.10.8720. View

17.

Paschka P, Marcucci G, Ruppert A, Mrozek K, Chen H, Kittles R . Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol. 2006; 24(24):3904-11. DOI: 10.1200/JCO.2006.06.9500. View

18.

Valk P, Verhaak R, Beijen M, Erpelinck C, Barjesteh van Waalwijk van Doorn-Khosrovani S, Boer J . Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med. 2004; 350(16):1617-28. DOI: 10.1056/NEJMoa040465. View

19.

Virappane P, Gale R, Hills R, Kakkas I, Summers K, Stevens J . Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party. J Clin Oncol. 2008; 26(33):5429-35. DOI: 10.1200/JCO.2008.16.0333. View

20.

Verhaak R, Wouters B, Erpelinck C, Abbas S, Beverloo H, Lugthart S . Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling. Haematologica. 2008; 94(1):131-4. PMC: 2625407. DOI: 10.3324/haematol.13299. View